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Abstract 22 
 23 
Excess production of reactive oxygen species (ROS) is known to cause apoptotic cell 24 
death. However, the molecular mechanisms whereby ROS induce apoptosis remain 25 
elusive. Here we show that the NHLRC2 thioredoxin-like domain protein is cleaved by 26 
caspase-8 in ROS-induced apoptosis in the HCT116 human colon cancer cell line. 27 
Treatment of HCT116 cells with the oxidant tert-butyl hydroperoxide (tBHP) induced 28 
apoptosis and reduced NHLRC2 protein levels, whereas pretreatment with the 29 
antioxidant N-acetyl-L-cysteine prevented apoptosis and the decrease in NHLRC2 30 
protein levels seen in tBHP-treated cells. Furthermore, the ROS-induced decrease in 31 
NHLRC2 protein levels was relieved by the caspase inhibitor z-VAD-fmk. We found 32 
that the thioredoxin-like domain of NHLRC2 interacted with a proenzyme form of 33 
caspase-8 and that caspase-8 cleaved NHLRC2 protein at Asp580 in vitro. Furthermore, 34 
siRNA-mediated knockdown of caspase-8 blocked the ROS-induced decrease in 35 
NHLRC2 protein levels. Both shRNA and CRISPR-Cas9-mediated loss of NHLRC2 36 
resulted in an increased susceptibility of HCT116 cells to ROS-induced apoptosis. 37 
These results suggest that excess ROS production causes a caspase-8-mediated decrease 38 
in NHLRC2 protein levels, leading to apoptotic cell death in colon cancer cells, and 39 
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indicate an important role of NHLRC2 in the regulation of ROS-induced apoptosis. 40 
  41 
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Introduction 42 
 43 
Reactive oxygen species (ROS), such as hydrogen peroxide and the hydroxyl radical, 44 
are generated from normal metabolic processes or toxic insults 1, 2. ROS at low levels 45 
can act as cell signaling molecules by reversibly oxidizing thiol groups in proteins, 46 
thereby modifying protein structure and function. On the other hand, high levels of ROS 47 
can harm cells by nonspecifically damaging macromolecules, including DNA, proteins 48 
and lipids. Therefore, maintenance of ROS homeostasis is essential for the regulation of 49 
a variety of cellular processes, such as cell survival, death and proliferation 1, 2. 50 
ROS are implicated in the induction or enhancement of apoptosis 3, 4. Regulation 51 
and execution of apoptosis are mainly accomplished by caspases, a family of aspartic 52 
acid-specific cysteine proteases 5, 6. Caspase-mediated cleavage of a large set of specific 53 
proteins is responsible for most apoptotic changes 7. On the basis of structural and 54 
functional characteristics, caspases involved in apoptosis are grouped into initiator 55 
(caspase-2, -8, -9 and -10) and effector (caspase-3, -6 and -7) caspases 8. Apoptosis is 56 
initiated by extracellular and intracellular signals via two main pathways, the death 57 
receptor-mediated (extrinsic) and the mitochondria-mediated (intrinsic) pathways 8. 58 
Among caspase family members, caspase-8 is a key mediator of apoptotic signals 59 
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associated with death receptors 9, 10, 11, whereas caspase-9 plays a pivotal role in 60 
mitochondria-mediated apoptosis 12. Both caspase-8 and -9 are involved in 61 
ROS-induced apoptosis 13, 14, 15, 16, although ROS production is thought to induce 62 
apoptosis mainly through the intrinsic pathway. 63 
Under normal physiological conditions, intracellular levels of ROS are strictly 64 
maintained to prevent cell damage 2. Detoxification of ROS is facilitated by 65 
non-enzymatic molecules or through antioxidant enzymes. Thioredoxin (Trx), which is 66 
present in every organism, is one of the important antioxidant proteins 17, 18. The 67 
catalytic site of Trx contains a Cys–X–X–Cys motif, where X represents any amino acid 68 
19, 20. These two cysteines are cycled between an active (reduced) dithiol form and an 69 
inactive (oxidized) disulfide form. In its active state, Trx scavenges ROS and keeps 70 
proteins in their reduced state. Trx, which constitutes a key component of a redox 71 
regulatory system in mammalian cells, is the best characterized regulator of the thiol 72 
group in proteins 21. However, there are numerous other Trx-like proteins, whose 73 
functions and interactors are unknown 22. 74 
NHL-repeat-containing protein 2 (NHLRC2) is a 79-kDa protein of 726 amino 75 
acids that consists of the N-terminal Trx-like domain and a C-terminal NHL (NCL-1, 76 
HT2A and LIN-41)-repeat domain. The NHL-repeat domains have been proposed to 77 
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form β-propeller structures 23, 24, similar to those of the WD40-repeat domain, 78 
suggesting their functions in protein–protein interactions. However, interactors of 79 
NHLRC2 have not been identified yet. The NHLRC2 gene has been found in many 80 
species, from flies to humans, and their sequences are highly conserved during 81 
evolution. A recent study reported that a mutation in the NHLRC2 gene in cattle was 82 
related to embryonic malformation 25, suggesting an important role in embryonic 83 
development. Based on the amino acid sequence, NHLRC2 is expected to be involved 84 
in the regulation of redox states of particular proteins. However, the roles and 85 
interactors of NHLRC2 are as yet unexplored. 86 
In this study, we report that NHLRC2 is cleaved by caspase-8 in ROS-induced 87 
apoptosis in the HCT116 human colon cancer cell line. We found that NHLRC2 protein 88 
levels were decreased in ROS-induced apoptosis in HCT116 cells. Caspase-8 was 89 
identified as the enzyme responsible for the decreased NHLRC2 levels in ROS-induced 90 
apoptosis. Furthermore, we show that loss of NHLRC2 resulted in an increased 91 
susceptibility of HCT116 cells to ROS-induced apoptosis. Taken together, these results 92 
suggest that excess ROS production causes a caspase-8-mediated decrease in NHLRC2 93 
protein levels, leading to apoptotic cell death in colon cancer cells, indicating an 94 
important role for NHLRC2 in the regulation of ROS-induced apoptosis. 95 
96 
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Results 97 
 98 
The oxidant tBHP reduces NHLRC2 protein levels through ROS production in HCT116 99 
cells 100 
To study the potential role of NHLRC2 in ROS-induced apoptosis, we examined 101 
the effects of the oxidant tert-butyl hydroperoxide (tBHP) on apoptotic cell death and 102 
NHLRC2 protein levels in HCT116 cells. The HCT116 human colon cancer cell line is 103 
a widely used cell line that is sensitive to a number of apoptosis-inducing agents 26, 27, 28, 104 
29. Here, we used tBHP to induce ROS production in the cells, because it is widely used 105 
as a better alternative to H2O2 in oxidative stress studies 30, 31, 32. Treatment of HCT116 106 
cells with tBHP caused a dose-dependent increase in the population of annexin 107 
V-positive apoptotic cells (Figure 1a and b). On the other hand, pretreatment with the 108 
antioxidant N-acetyl-L-cysteine (NAC) blocked the tBHP-induced increase in apoptotic 109 
cells (Figure 1a and b). Furthermore, treatment with tBHP resulted in a marked decrease 110 
in NHLRC2 protein levels, whereas pretreatment with NAC relieved the tBHP-induced 111 
decrease in NHLRC2 protein levels (Figure 1c). The mRNA levels of NHLRC2 gene 112 
were not affected by tBHP treatment (Figure 1d). These results indicated that tBHP 113 
treatment induced apoptotic cell death and reduced NHLRC2 protein levels through 114 
ROS production in HCT116 cells. 115 
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 116 
Caspases are involved in the ROS-induced decrease in NHLRC2 protein levels 117 
Caspases play a critical role in protein cleavage in the apoptotic pathway. To find 118 
out whether caspases were involved in the decreased NHLRC2 protein levels in 119 
ROS-induced apoptosis, we first examined the activation of caspases in tBHP-treated 120 
HCT116 cells. We assessed caspase activation by the disappearance of proenzyme using 121 
immunoblotting analysis. It was difficult to detect the large and small subunits of 122 
processed caspases under the conditions of these assays, probably due to the short 123 
half-life of the active caspases in the cells. Treatment of HCT116 cells with tBHP 124 
caused a dose-dependent decrease in the proenzyme levels of initiator caspases 125 
(caspase-2, -8 and -9) and effector caspases (caspase-3, -6 and -7) (Figure 2a). 126 
Furthermore, activation of caspase-8 by tBHP treatment was confirmed by measuring 127 
caspase-8 activity in HCT116 cells (Figure 2b). These results indicated that tBHP 128 
treatment induced activation of both caspases that are involved in the intrinsic or 129 
extrinsic pathway. We next tested the effects of z-VAD-fmk, a caspase inhibitor with 130 
broad specificity, on apoptosis and the decreased NHLRC2 protein levels in 131 
tBHP-treated HCT116 cells. The z-VAD-fmk relieved the tBHP-induced decrease in 132 
NHLRC2 protein levels with concomitant restoration of procaspase levels, except for 133 
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procaspase-2 levels (Figure 2a). Furthermore, tBHP-induced apoptosis was efficiently 134 
abrogated by pretreatment with z-VAD-fmk (Figure 2c and d). These results suggested 135 
an involvement of caspases in the decreased NHLRC2 protein levels in ROS-induced 136 
apoptosis. 137 
 138 
Overexpression of caspase-1, -2, -4, -8, -9 or -10 dramatically decreases NHLRC2 139 
protein levels 140 
To examine whether caspases cleave NHLRC2 protein in ROS-induced apoptosis, 141 
NHLRC2 tagged with an HA-tag at the C-terminus (NHLRC2-HA) was 142 
co-overexpressed individually with a series of caspases tagged with myc and FLAG 143 
tags (myc-caspase-FLAG) at the N- and C-termini, respectively, in 293FT cells. 144 
Expression levels of these proteins were examined by immunoblotting analysis. 145 
Overexpression of procaspases is sufficient to induce their autoactivation 33, 34, 35. As 146 
shown in Figure 3, expression of myc-caspase-FLAG proteins for caspase-1, -2, -4, -8, 147 
-9 and -10 was hardly observed in the absence of z-VAD-fmk, whereas the treatment 148 
with z-VAD-fmk yielded an increase in these caspases’ proenzyme levels, indicating 149 
that these myc-caspase-FLAG proteins were expressed as active forms (Figure 3). 150 
Immunoblotting analysis using an anti-HA antibody showed that co-overexpression 151 
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with caspase-1, -2, -4, -8, -9 or -10, but not caspase-3, -6 or -7, resulted in a marked 152 
decrease in NHLRC2-HA protein levels (Figure 3). Furthermore, treatment with 153 
z-VAD-fmk blocked the decrease in NHLRC2-HA protein levels by co-overexpression 154 
of these caspases (Figure 3), indicating that enzyme activity of caspases was required to 155 
achieve the dramatic decrease in NHLRC2 protein levels. It was reported that activated 156 
caspases cleaved a DVPD sequence within an HA-tag, causing loss of immunoreactivity 157 
against the anti-HA antibody 36. Therefore, NHLRC2-HA protein levels were also 158 
assessed by immunoblotting using anti-NHLRC2 polyclonal antibody raised against 159 
full-length human NHLRC2 protein. Immunoblotting analysis using an anti-NHLRC2 160 
antibody showed similar results to those with the anti-HA antibody (Figure 3), 161 
indicating that co-overexpression of caspase-1, -2, -4, -8, -9 or -10 caused the marked 162 
decrease in NHLRC2-HA protein levels, but not the cleavage of the HA-tag. Additional 163 
bands corresponding to NHLRC2 fragments cleaved by caspase-1, -2, -4, -8, -9 or -10 164 
were barely detected in immunoblotting analysis, suggesting that the cleaved forms of 165 
NHLRC2 by these caspases were rapidly degraded in the cells. On the other hand, in the 166 
immunoblotting analysis using an anti-NHLRC2 antibody, co-overexpression of 167 
caspase-7 resulted in the appearance of an additional 58-kDa band with a concomitant 168 
slight decrease in a 78-kDa band corresponding to full-length NHLRC2, indicating that 169 
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the cleavage by caspase-7 produced a stable cleaved form of NHLRC2. These results 170 
suggested that cleavage sites of NHLRC2 may be different between caspase-1, -2, -4, -8, 171 
-9 or -10 and caspase-7, resulting in cleaved forms with different stabilities. 172 
 173 
The Trx-like domain of NHLRC2 interacts with proenzyme forms of caspase-1, -2, -4, -8, 174 
-9 and -10 175 
To clarify whether caspases recognize NHLRC2 as a substrate, we investigated 176 
the interaction between NHLRC2 and caspases. Since co-overexpression with caspases 177 
resulted in the dramatic decrease in NHLRC2-HA protein levels described above, we 178 
substituted the catalytic cysteine residue in each myc-caspase-FLAG with serine to 179 
express catalytically inactive forms of caspases (myc-caspase-FLAG CS mutants). The 180 
CS mutant of each caspase was co-overexpressed with NHLRC2-HA in 293FT cells. 181 
Expression of myc-caspase-FLAG CS mutants was easily detected by both anti-FLAG 182 
and anti-myc antibodies, unlike that of their wild-type proteins, indicating that the CS 183 
mutants were expressed as catalytically inactive forms (Figure 4a). Nonetheless, the 184 
intensity of bands corresponding to caspase-2 and -10 CS mutants was remarkably 185 
lower compared with those of other caspases, due to a low solubility in Co-IP buffer, by 186 
the formation of large aggregates in the cells (see below). The CS mutants of caspase-1, 187 
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-2, -4, -8, -9 and -10 were co-immunoprecipitated together with NHLRC2-HA by 188 
anti-HA antibody (Figure 4b), whereas co-immunoprecipitation with the CS mutants of 189 
caspase-3, -6 and -7 was not observed. Furthermore, reciprocal co-immunoprecipitation 190 
assays using anti-FLAG or anti-myc antibody also revealed that NHLRC2-HA 191 
interacted specifically with the CS mutants of caspase-1, -2, -4, -8, -9 and -10 (Figure 4c 192 
and d). 193 
To identify the region of NHLRC2 that is required for interaction with caspases, 194 
we tested truncated forms of NHLRC2 protein for their ability to bind to 195 
myc-caspase-4-FLAG CS mutant (Figure 5a). Myc-caspase-4-FLAG CS mutant 196 
interacted specifically with the Trx-like domain, but not the NHL-repeat domain, of 197 
NHLRC2 (Figure 5b). Furthermore, interactions between the Trx-like domain of 198 
NHLRC2 and the CS mutants of caspase-1, -2, -8, -9 and -10 were also observed 199 
(Figure 5c). These results suggested that the Trx-like domain of NHLRC2 bound to the 200 
proenzyme forms of caspase-1, -2, -4, -8, -9 and -10. 201 
To further confirm the interaction between NHLRC2 and caspases-1, -2, -4, -8, -9 202 
and -10, we examined the localization of NHLRC2-HA and myc-caspase-FLAG CS 203 
mutants in HEK293 cells by immunofluorescence analysis. NHLRC2-HA was 204 
distributed in the cytosol when overexpressed alone in the cells (Figure 5d, top panels). 205 
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CS mutants of caspase-2, -8 and -10 formed large aggregates in the cytosol, whereas 206 
wild-type caspase-2 and caspase-8 and -10 were localized in the nucleus and cytosol, 207 
respectively (Figure 5e). Interestingly, NHLRC2-HA that was co-overexpressed with 208 
the CS mutant of caspase-2, -8 or -10 was incorporated into their aggregates (Figure 5d). 209 
On the other hand, co-overexpression with CS mutants of caspase-1, -4 or -9 did not 210 
affect the cytosolic distribution of NHLRC2-HA, and these CS mutants were distributed 211 
in the cytosol, similar to NHLRC2-HA (Figure 5d). Together, these results suggested 212 
that the Trx-like domain of NHLRC2 interacted with proenzyme forms of caspase-1, -2, 213 
-4, -8, -9 and -10. 214 
 215 
Caspase-8 cleaves NHLRC2 protein at Asp580 in ROS-induced apoptosis 216 
To identify the caspase that cleaves NHLRC2 protein, we carried out a cell-free 217 
caspase assay using active forms of recombinant caspase-1, -2, -4, -8, -9 and -10. 218 
Whole-cell lysates from 293FT cells transfected with expression vectors for 219 
NHLRC2-HA were incubated individually with each recombinant caspase. Cleavage of 220 
NHRLC2-HA was evaluated by immunoblotting using an anti-NHLRC2 antibody. As 221 
shown in Figure 6a, additional bands of about 58 kDa were detected after incubation 222 
with caspase-1, -8 or -9, in addition to the main 78-kDa band corresponding to 223 
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full-length NHLRC2-HA. The appearance of the 58-kDa band was suppressed 224 
significantly in the presence of z-VAD-fmk. These results indicated that caspase-1, -8 225 
and -9 cleaved NHLRC2 in vitro. Interestingly, the mobilities of the bands that appeared 226 
after incubation with caspase-1, -8 or -9 were slightly different (Figure 6a), suggesting 227 
that caspase-1, -8 and -9 cleaved NHLRC2 at different sites. 228 
To identify the caspase responsible for the cleavage of NHRLC2 in ROS-induced 229 
apoptosis, we depleted a series of caspases in HCT116 cells using siRNA. We did not 230 
test siRNAs for caspase-1 and -10, because their expression was not observed in 231 
HCT116 cells by immunoblotting analysis (data not shown). Efficient knockdown of 232 
endogenous caspase proteins was confirmed by immunoblotting (Figure 6b). Only 233 
knockdown of caspase-8 obviously prevented the ROS-induced decrease in NHLRC2 234 
protein levels, whereas the depletion of other caspases did not restore the decreased 235 
NHRLC2 protein levels (Figure 6c). These results indicated that caspase-8 cleaved 236 
NHLRC2 protein in ROS-induced apoptosis in HCT116 cells. 237 
Caspases typically cleave at the C-terminal side of the last Asp residue in the 238 
tetra-peptide sequence X–X–X–D of the target protein. To identify the caspase-8 239 
cleavage site, we introduced Asp to Asn mutations at several predicted candidate sites in 240 
the NHLRC2 sequence. These mutants were expressed in 293FT cells and subjected to 241 
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the cell-free caspase assay using the active form of recombinant caspase-8. As shown in 242 
Figure 6d, of the mutations introduced, only the mutation at Asp580 efficiently 243 
prevented the cleavage of NHLRC2 protein by caspase-8, indicating that caspase-8 244 
cleaved NHLRC2 protein at Asp580. 245 
 246 
Loss of NHLRC2 increases the susceptibility of cells to apoptosis induced by ROS or 247 
etoposide 248 
To clarify the significance of caspase-8-mediated cleavage of NHLRC2 protein in 249 
ROS-induced apoptosis, we knocked down NHLRC2 in HCT116 cells using 250 
retrovirus-mediated shRNA and examined the effects on cell proliferation and 251 
ROS-induced apoptosis. Endogenous NHLRC2 protein was knocked down efficiently 252 
by two different shRNAs (Figure 7a). The decrease in NHLRC2 protein levels resulted 253 
in the suppression of cell proliferation regardless of the presence of tBHP (Figure 7b). 254 
Furthermore, NHLRC2 knockdown did not induce apoptosis in the absence of tBHP but 255 
promoted apoptosis caused by tBHP at relatively low concentrations (Figure 7c and d). 256 
To further confirm these results, a lentivirus-mediated CRISPR-Cas9 strategy was 257 
utilized. Endogenous NHLRC2 protein was efficiently depleted by two different 258 
sgRNAs (Supplementary Figure 1a). In accordance with the results of shRNA-mediated 259 
16 
 
knockdown, CRISPR-Cas9-mediated loss of NHLRC2 resulted in the suppression of 260 
cell proliferation and the increased susceptibility to apoptosis caused by tBHP at 261 
relatively low concentrations (Supplementary Figure 1b-d). Together, these results 262 
suggested that the caspase-8-mediated decrease in NHLRC2 protein levels is an 263 
important step in ROS-induced apoptosis in HCT116 cells. 264 
Furthermore, we examined an involvement of NHLRC2 in ROS-induced 265 
apoptosis in the HEK293 human embryonic kidney cells. Treatment of HEK293 cells 266 
with tBHP resulted in a marked decrease in NHLRC2 protein levels, whereas 267 
pretreatment with z-VAD-fmk relieved the tBHP-induced decrease in NHLRC2 protein 268 
levels (Supplementary Figure 2a). Furthermore, shRNA-mediated knockdown of 269 
NHLRC2 increased the sensitivity of HEK293 cells to tBHP-induced apoptosis 270 
(Supplementary Figure 2b-d). These results suggested that caspase-mediated 271 
downregulation of NHLRC2 is an important step in ROS-induced apoptosis in various 272 
cell types. 273 
NHLRC2 protein interacted with and was cleaved by not only caspase-8 but also 274 
caspase-1, -2, -4, -9 or -10 in vitro (Figure 3-5), suggesting that NHLRC2 was involved 275 
in apoptosis induced by stimuli other than ROS. Therefore, we examined the effect of 276 
NHLRC2 loss on etoposide-induced apoptosis. Etoposide is known to cause 277 
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DNA-damage by inhibiting topoisomerase II, leading to apoptosis mainly through 278 
mitochondrial pathway 37, 38. shRNA-mediated knockdown of NHLRC2 promoted 279 
apoptosis induced by etoposide in HCT116 cells (Figure 8a and b), suggesting that 280 
NHLRC2 may play an important role in various types of caspase-dependent cell death. 281 
Discussion 282 
 283 
In this study, we demonstrated that the NHLRC2 Trx-like domain protein is a novel 284 
caspase-8 substrate that is involved in the regulation of ROS-induced apoptosis. We 285 
show that treatment with the oxidant tBHP caused a marked decrease in NHLRC2 286 
protein levels in HCT116 cells. On the other hand, the tBHP-induced decrease in 287 
NHLRC2 protein levels was prevented by the ROS-scavenger NAC or the caspase 288 
inhibitor z-VAD-fmk, indicating that NHLRC2 protein levels are regulated through 289 
caspase activity in response to ROS production. We show that caspase-8 cleaved 290 
NHLRC2 in ROS-induced apoptosis. Furthermore, loss of NHLRC2 resulted in an 291 
increase in susceptibility of HCT116 cells to ROS-induced apoptosis. These results 292 
suggest that caspase-8-mediated cleavage of NHLRC2 protein is an important step in 293 
the ROS-induced apoptotic pathway in HCT116 cells, indicating a key role of NHLRC2 294 
in ROS-induced apoptosis. 295 
The cleavage of NHLRC2 protein by caspase-8 in vitro yielded an additional 296 
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58-kDa fragment detected by immunoblotting analysis (Figure 6). In contrast, tBHP 297 
treatment of HCT116 cells resulted in a decrease in the levels of the 78-kDa band 298 
corresponding to full-length NHLRC2 without the appearance of additional bands 299 
(Figure 1, 2). Furthermore, co-overexpression of myc-caspase-8-FLAG dramatically 300 
decreased full-length NHLRC2-HA protein levels in 293FT cells; however, processed 301 
fragments of NHLRC2-HA were not observed (Figure 3). Namely, fragment of 302 
NHLRC2 cleaved in in vitro experiment was detected, whereas fragment of NHLRC2 303 
cleaved within the cells was not detected. These results suggest that cleaved fragments 304 
of NHLRC2 by caspase-8 may be further processed by other proteases within the cells. 305 
Recently, Polkoff et al. reported that a mutation in a highly conserved 306 
protein-coding region of the NHLRC2 gene in cattle is related to embryonic 307 
malformation 25. Furthermore, homozygous deletion of the NHLRC2 gene in mice 308 
yielded an embryonic lethality 39. On the other hand, NHLRC2 was identified as a blood 309 
biomarker for Alzheimer’s disease 40. Therefore, it has been indicated that NHLRC2 310 
plays an important role in embryonic development and is related to human diseases. 311 
However, the functions and physiological roles of NHLRC2 had been totally 312 
unexplored. In this study, we show that NHLRC2 acted as an antioxidant protein in the 313 
regulation of ROS-induced apoptosis. Furthermore, the depletion of NHLRC2 314 
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significantly suppressed cell proliferation in HCT116 cells, even in the absence of 315 
excessive ROS production. Thus, NHLRC2 may have an additional role in the 316 
regulation of cell proliferation, in addition to apoptosis. 317 
Here, we show that the Trx-like domain of NHLRC2 interacted with the 318 
proenzymes of caspases. In general, the two cysteine residues in the catalytic site of the 319 
Trx-like domain are thought to regulate redox states of thiol groups of proteins 19, 20. 320 
Caspases are a family of cysteine proteases that use a cysteine thiol group in the active 321 
site to cleave a peptide bond after an Asp residue of the target protein. Thus, NHLRC2 322 
may participate in caspase activation by regulating the redox state of the catalytic 323 
cysteine thiol group of caspases. 324 
NHL-repeat domains have been demonstrated to form β-propeller structures 23, 24 325 
similar to those of the WD40-repeat domain, which is involved in protein–protein 326 
interactions. Many NHL-repeat domain proteins have additional motifs—including 327 
RING domains, B-box zinc finger domains and coiled-coil domains—indicating their 328 
diverse functions in various cellular pathways. For example, NHL-repeat-containing 329 
protein 1 (NHLRC1), which is a causative gene for Lafora disease, an autosomal 330 
recessive neurodegenerative disorder, encodes an E3 ubiquitin ligase that consists of a 331 
RING domain and an NHL-repeat domain 41, 42. The NHL-repeat domain of NHLRC1 332 
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has been shown to bind to the glucan phosphatase laforin. In contrast, the NHL-repeat 333 
domain of the Drosophila TRIM-NHL protein Brain tumor (Brat) has been reported to 334 
bind directly to hunchback RNA, leading to repression of its translation, suggesting a 335 
novel function of the NHL-repeat domain in translational regulation through RNA 336 
binding43, 44. Among NHL-repeat domain proteins, NHLRC2 is the only known protein 337 
containing the Trx-like domain. However, interactors of the NHL-repeat domain of 338 
NHLRC2 have not yet been identified. To better understand the physiological role of 339 
NHLRC2, identifying proteins that interact with the NHL-repeat domain of NHLRC2 is 340 
important. 341 
Maintenance of ROS homeostasis is recognized as a key process underlying the 342 
molecular basis of many diseases, such as cancers. In cancer cells, increased ROS 343 
generation, which results from elevated metabolic activity and mitochondrial 344 
dysfunction, contributes to tumor development and progression 1, 4. Cancer cells are 345 
more sensitive to rapid increases in ROS levels than normal cells. Indeed, ROS 346 
production is a common characteristic of many anticancer therapies 45. In this study, we 347 
show that the downregulation of NHLRC2 expression caused an increased susceptibility 348 
of HCT116 cells to ROS-induced apoptosis. Therefore, NHLRC2 may be a possible 349 
drug target to sensitize cancer cells to ROS-dependent apoptosis induced by cancer 350 
21 
 
chemotherapy. 351 
In conclusion, the Trx-like domain protein NHLRC2 is a novel caspase-8 352 
substrate that is involved in the regulation of ROS-induced apoptosis, and ROS-induced 353 
cleavage of NHLRC2 by caspase-8 leads to apoptotic cell death. Taken together, these 354 
results indicate the important role of NHLRC2 in ROS-induced apoptosis. 355 
  356 
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Materials and methods 357 
 358 
Antibodies and constructs 359 
Anti-FLAG (M2) (F1804) and anti-β-actin (A2066) antibodies were purchased 360 
from Sigma-Aldrich (St. Louis, MO, USA). Peroxidase-conjugated anti-DYKDDDDK 361 
tag (015-22391) and peroxidase-conjugated anti-c-myc tag (014-21901) monoclonal 362 
antibodies were purchased from Wako Pure Chemical Industries (Osaka, Japan). 363 
Anti-NHLRC2 (ab88725) antibody was purchased from AbCam (Eugene, OR, USA). 364 
Anti-caspase-2 (11B4) antibody (MAB3507) was purchased from Millipore (Billerica, 365 
MA, USA). Anti-caspase-1 (#3866), anti-caspase-3 (#9665), anti-caspase-4 (#4450), 366 
anti-caspase-6 (#9762), anti-caspase-7 (#12827), anti-caspase-8 (#9746), anti-caspase-9 367 
(#9508) and anti-HA-tag (C29F4) (#3724) antibodies were purchased from Cell 368 
Signaling Technologies (Danvers, MA, USA). 369 
Human NHLRC2 cDNA was amplified from reverse transcription products from 370 
HCT116 cells using the primers shown in Supplemental Table S1. The cDNAs encoding 371 
full-length or truncated forms of NHLRC2 tagged with HA at the N- or C-terminus 372 
were subcloned into a pCI-neo vector at XhoI and NotI sites using the primers shown in 373 
Supplemental Table S1. Several Asp residues in the NHLRC2 cDNA were mutated into 374 
asparagine using a QuickChange Site-Directed Mutagenesis kit (Takara Bio, Shiga, 375 
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Japan). Sequences for forward primers used in the mutagenesis are shown in 376 
Supplemental Table S1. All expression vectors were verified by DNA sequencing. 377 
The cDNAs for human caspases were amplified from reverse transcription 378 
products from HEK293 cells using the primers shown in Supplemental Table S1. Myc 379 
and FLAG tags were added at the N- and C-termini, respectively, of each caspase cDNA 380 
by PCR, and then myc-caspase-FLAG cDNAs were subcloned into a pcDNA3 vector at 381 
KpnI and NotI sites. The catalytic cysteine residues in caspase cDNAs were mutated 382 
into serine using a QuickChange Site-Directed Mutagenesis kit (Takara Bio). Sequences 383 
for the forward primers used in the mutagenesis are shown in Supplemental Table S1. 384 
All expression vectors were verified by DNA sequencing. 385 
 386 
Cells, treatment, and siRNA transfection 387 
The HCT116 human colon cancer cell line and the HEK293 human embryonic 388 
kidney cell line (both from ATCC, Maryland, MD, USA) were cultured at 37°C with 5% 389 
CO2 in Dulbecco’s Modified Eagle Medium (Wako Pure Chemical Industries), 390 
supplemented with 10% fetal calf serum and penicillin/streptomycin. For tBHP 391 
(#458139, Sigma-Aldrich) or etoposide (E1383, Sigma-Aldrich) treatment, cells were 392 
seeded in 6- or 12-well plates at a density of 5 × 105 and 2.5 × 105 cells per well, 393 
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respectively. After 24 h, the culture medium was switched to a medium containing 394 
chemical, and the cells were incubated for a further 24 h. For scavenging ROS or 395 
inhibiting caspase activity, cells were preincubated for 1 h with NAC (A7250, 396 
Sigma-Aldrich) and z-VAD(OMe)-fmk (z-VAD-fmk, ab120487, AbCam), respectively. 397 
The siRNAs against caspases were purchased from Invitrogen (Asheville, NC, 398 
USA). Sequences for each siRNA are shown in Supplemental Table S2. Cells were 399 
transfected with siRNA using Lipofectamine RNAiMAX (Invitrogen) according to the 400 
manufacturer’s reverse transfection protocol. Briefly, cells were seeded with siRNA (10 401 
pmol)–Lipofectamine RNAiMAX (5 µL) complexes in 6-well plates at a density of 5 × 402 
105 cells per well. After 24 h, the culture medium was switched to a medium containing 403 
300 µM tBHP, and the cells were incubated for a further 24 h. 404 
 405 
Cell lysates, immunoblotting, co-immunoprecipitation and qRT-PCR 406 
Cells were lysed and subjected to immunoblotting as described previously46, 47. 407 
For co-immunoprecipitation, cells were lysed in Co-IP buffer (50 mM Tris-HCl, pH 7.5; 408 
150 mM NaCl; 5 mM MgCl2; 10% glycerol and 1% NP-40) supplemented with 409 
cOmplete EDTA-Free Protease Inhibitor (Sigma-Aldrich) by incubation for 30 min at 410 
4°C. Cell pellets were removed by centrifugation, and the supernatants were precleaned 411 
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by incubation with rat or mouse IgG and Protein G Sepharose (GE Healthcare Life 412 
Sciences, Pittsburgh, PA, USA) for 30 min at 4°C under gentle rotation. After 413 
centrifugation, the supernatants were co-immunoprecipitated by incubation with 414 
anti-HA affinity matrix (11815016001, Sigma-Aldrich), anti-DYKDDDDK tag antibody 415 
beads (018-22783, Wako Pure Chemical Industries) or anti-c-myc (9E10) antibody 416 
(sc-40, Santa Cruz Biotechnology, Santa Cruz, CA, USA) conjugated with Protein G 417 
Sepharose at 4°C under gentle rotation overnight. The beads were washed with Co-IP 418 
buffer three times and then boiled in Laemmli sample buffer. The eluates were subjected 419 
to immunoblotting. 420 
qRT-PCR was performed using the primers shown in Supplemental Table S1 as 421 
described previously48. 422 
 423 
Immunofluorescence microscopy 424 
HEK293 cells seeded on to 12-mm diameter glass coverslips placed in 24-well 425 
plates were transfected with NHLRC2-HA expression vector alone or with 426 
myc-caspase-FLAG CS mutant vectors using Lipofectamine 3000 (Invitrogen). After 24 427 
h, the transfected cells were fixed with 4% paraformaldehyde in phosphate-buffered 428 
saline (PBS) for 15 min, washed with PBS three times, and then permeabilized/blocked 429 
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with 0.3% Triton X-100/5% nonfat dry milk in PBS for 30 min. For immunostaining, 430 
the cells were first incubated with anti-HA (C29F4) and anti-FLAG (M2) antibodies for 431 
1 h at room temperature. Both antibodies were diluted in 0.3% Triton X-100/5% nonfat 432 
dry milk in PBS at a dilution of 1:1000. Following incubation, cells were washed with 433 
PBS three times and subsequently incubated with Alexa Fluor 555 conjugated 434 
anti-mouse IgG and Alexa Fluor 488 conjugated anti-rabbit IgG antibodies (both from 435 
Invitrogen) at a dilution of 1:1000 for 1 h at room temperature. Cells were washed with 436 
PBS three times, mounted in Fluorescence Mounting Medium (Dako, Santa Clara, CA, 437 
USA), and examined using a TCS SP5 laser-scanning confocal microscope (Leica 438 
Microsystems, Wetzlar, Germany). 439 
 440 
In vitro cleavage assay of NHLRC2 protein by caspases 441 
293FT cells (Invitrogen) were transfected with expression vectors for wild-type or 442 
mutant NHLRC2-HA using polyethyleneimine “MAX” transfection reagent 443 
(Polysciences, Warrington, PA, USA) and then lysed in Cell Lysis Buffer (BioVision, 444 
Milpitas, CA, USA). Aliquots of lysates were incubated with 1 unit of recombinant 445 
active caspases (BioVision) in 1× Reaction Buffer (BioVision) at 37°C for 1 h. 446 
Reactions were terminated by adding Laemmli sample buffer and boiling at 95°C for 5 447 
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min. Cleavage was evaluated by immunoblotting using an anti-NHLRC2 antibody. 448 
 449 
Production and transduction of retroviruses and lentiviruses 450 
The oligonucleotides encoding shRNA against human NHLRC2, shown in 451 
Supplemental Table S3, were annealed and then inserted into the 452 
pSIREN-RetroQ-ZsGreen vector (Takara Bio) as described previously 49. Negative 453 
control shRNA oligonucleotide was purchased from Takara Bio. GP2-293 retroviral 454 
packaging cells (Takara Bio) were transfected with both retroviral and pAmpho 455 
envelope vectors using a CalPhos Transfection kit (Takara Bio). 456 
Oligonucleotides encoding sgRNA against human NHLRC2, shown in 457 
Supplemental Table S3, were annealed and then inserted into the pL-CRISPR.EFS.GFP 458 
vector (Addgene, Cambridge, MA, USA) 50. Lentivirus was produced by transient 459 
transfection of 293FT cells using polyethyleneimine “MAX” transfection reagent. Viral 460 
constructs were cotransfected with pMDL, pRev and pVSVG vectors (kind gifts from 461 
Dr. Kinichi Nakashima, Kyushu University, Japan). 462 
Culture supernatants containing retrovirus or lentivirus were collected 48 h after 463 
transfection. HCT116 cells were transduced with virus-containing medium 464 
supplemented with 8 µg/mL polybrene by centrifugation at 1000 × g for 2 h at 32°C and 465 
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then further cultured for 8 h. The virus-containing medium was removed and replaced 466 
with fresh medium. After three days, ZsGreen or EGFP-positive cells were sorted using 467 
a FACSAriaII (BD Biosciences, San Jose, CA, USA) and reseeded in tissue culture 468 
plates for subsequent experiments. 469 
 470 
Caspase-8 activity measurement and cell proliferation assay 471 
Cells were seeded in 96-well plates at a density of 5 × 103 cells per well in 100 μL 472 
culture medium. After 24 h, the culture medium was switched to medium with or 473 
without tBHP. Caspase-8 activity and cellular proliferation were analyzed using 474 
Caspase-Glo8 assay (Promega, Madison, WI, USA) and Cell Counting Kit-8 (Dojindo, 475 
Kumamoto, Japan), respectively, according to the manufacturer’s protocols. 476 
 477 
Flow cytometry analysis of apoptotic cells 478 
Cells were seeded in 24-well plates at a density of 2.5 × 104 cells per well in 500 479 
μL culture medium. After 24 h, the culture medium was switched to medium with or 480 
without tBHP or etoposide, and apoptotic cells were assessed using an APC Annexin V 481 
Apoptosis Detection kit (BD Biosciences). Flow cytometry data were acquired using a 482 
FACSAriaII and analyzed with FlowJo software (Tomy Digital Biology, Tokyo Japan) 483 
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as described previously 48, 51. 484 
 485 
Statistical analysis 486 
Data are expressed as the mean ± standard deviation (SD). Statistical analyses 487 
were performed using an unpaired two-tailed Student’s t test. Differences at P < 0.05 488 
were considered to be statistically significant.  489 
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Figure legends 656 
 657 
Figure 1. The oxidant tBHP reduces NHLRC2 protein levels through ROS 658 
production in HCT116 cells. (a, b) Percentages of cells that underwent apoptosis for 659 
HCT116 cells treated with tBHP and NAC. (a) Numbers adjacent to the outline indicate 660 
the percentage of cells in each area. (b) The sum of annexin V+PI− and annexin V+PI+ 661 
populations in (a) is represented as the percentage of annexin V+ cells. Data represent 662 
the mean ± SD based on three independent experiments. *P < 0.05. (c) Immunoblotting 663 
analysis of NHLRC2 in HCT116 cells treated with tBHP and NAC. Actin was used as a 664 
loading control. (d) Quantitative RT-PCR analysis of NHLRC2 gene in HCT116 cells 665 
treated with tBHP. The mRNA expression levels of NHLRC2 were normalized against 666 
those of β-actin. The results are shown as the values relative to 0 µM tBHP cells. (a–d) 667 
Data are representative of three independent experiments.  668 
 669 
Figure 2. Inhibition of caspase activity prevents ROS-induced decrease in 670 
NHLRC2 protein levels in HCT116 cells. (a) Immunoblotting analysis of NHLRC2 671 
and caspases in HCT116 cells treated with tBHP and z-VAD-fmk. (b) Caspase-8 activity 672 
in HCT116 cells treated with tBHP. The results are shown as the values relative to 0 µM 673 
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tBHP cells. (c, d) Percentages of cells that underwent apoptosis for HCT116 cells 674 
treated with tBHP and z-VAD-fmk. (c) Numbers adjacent to the outline indicate the 675 
percentage of cells in each area. (d) The sum of annexin V+PI− and annexin V+PI+ 676 
populations in (c) is represented as the percentage of annexin V+ cells. Data represent 677 
the mean ± SD based on three independent experiments. *P < 0.05. (a–d) Data are 678 
representative of three independent experiments. 679 
 680 
Figure 3. Overexpression of caspase-1, -2, -4, -8, -9 or -10 dramatically diminishes 681 
NHLRC2-HA protein. Immunoblotting analysis of NHLRC2-HA and 682 
myc-CASP-FLAG proteins in 293FT cells. Actin was used as a loading control. Data 683 
are representative of three independent experiments. 684 
 685 
Figure 4. NHLRC2 interacts with the catalytically inactive forms of caspase-1, -2, 686 
-4, -8, -9 and -10. (a–d) Co-immunoprecipitation analysis of NHLRC2-HA and 687 
myc-CASP-FLAG CS mutants. Data are representative of three independent 688 
experiments. * Indicates endogenous c-myc protein. IP, immunoprecipitation; WCL, 689 
whole-cell lysate. 690 
 691 
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Figure 5. The Trx-like domain of NHLRC2 interacts with catalytically inactive 692 
caspases. (a) Schematic illustration of HA-NHLRC2, HA-Trx and HA-NHL. HA, 693 
HA-tag; NHL, NHL-repeat domain; Trx, thioredoxin-like domain. (b) 694 
Co-immunoprecipitation analysis of HA-NHLRC2, HA-Trx or HA-NHL with 695 
myc-CASP4-FLAG CS mutant. (c) Co-immunoprecipitation analysis of HA-Trx and 696 
myc-CASP-FLAG CS mutants. (d, e) Immunofluorescence images for NHLRC2-HA 697 
and wild-type and catalytically inactive (CS) myc-CASP-FLAG in HEK293 cells. (b–e) 698 
Data are representative of three independent experiments. 699 
 700 
Figure 6. Caspase-8 cleaves NHLRC2 protein at Asp580 in ROS-induced apoptosis. 701 
(a, d) Cell-free caspase cleavage assay of NHLRC2. (b, c) Immunoblotting analyses of 702 
caspases and NHLRC2 in HCT116 cells transfected with siRNAs for caspases. (a–d) 703 
Data are representative of three independent experiments. 704 
 705 
Figure 7. shRNA-mediated knockdown of NHLRC2 increases the susceptibility of 706 
HCT116 cells to ROS-induced apoptosis. (a) Immunoblotting analysis of NHLRC2 in 707 
HCT116 cells transduced with retrovirus for shRNAs for control (sh-Control) or 708 
NHLRC2 (sh-NHLRC2-#3 and -#5). (b–d) Analyses of cell proliferation (b) and 709 
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apoptosis (c, d) in HCT116 cells transduced with retrovirus for sh-Control, 710 
sh-NHLRC2-#3 or -#5. (b) *P < 0.05. (c) Numbers adjacent to the outline indicate the 711 
percentage of cells in each area. (d) The sum of annexin V+PI− and annexin V+PI+ 712 
populations in (c) is represented as the percentage of annexin V+ cells. Data represent 713 
the mean ± SD based on three independent experiments. *P < 0.05. (a–d) Data are 714 
representative of three independent experiments. 715 
 716 
Figure 8. shRNA-mediated knockdown of NHLRC2 increases the susceptibility of 717 
HCT116 cells to etoposide-induced apoptosis. (a, b) Analyses of apoptosis in HCT116 718 
cells transduced with retrovirus for sh-Control, sh-NHLRC2-#3 or -#5. (a) Numbers 719 
adjacent to the outline indicate the percentage of cells in each area. (b) The sum of 720 
annexin V+PI− and annexin V+PI+ populations in (a) is represented as the percentage of 721 
annexin V+ cells. Data represent the mean ± SD based on three independent experiments. 722 
*P < 0.05. 723 
 724 
Supplementary Figure 1. CRISPR-Cas9-mediated loss of NHLRC2 increases the 725 
susceptibility of HCT116 cells to ROS-induced apoptosis. (a) Immunoblotting 726 
analysis of NHLRC2 in HCT116 cells transduced with lentivirus for CRISPR-Cas9 and 727 
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sgRNAs for ZsGreen (sg-ZsGreen) or NHLRC2 (sg-NHLRC2-T24 and -T36). (b–d) 728 
Analyses of cell proliferation (b) and apoptosis (c, d) in HCT116 cells transduced with 729 
lentivirus for sg-ZsGreen, sg-NHLRC2-T24, or -T36. (b) *P < 0.05. (c) Numbers 730 
adjacent to the outline indicate the percentage of cells in each area. (d) The sum of 731 
annexin V+PI− and annexin V+PI+ populations in (c) is represented as the percentage of 732 
annexin V+ cells. Data represent the mean ± SD based on three independent experiments. 733 
*P < 0.05. (a–d) Data are representative of three independent experiments. 734 
 735 
Supplementary Figure 2. shRNA-mediated knockdown of NHLRC2 increases the 736 
susceptibility of HEK293 cells to ROS-induced apoptosis. (a) Immunoblotting 737 
analysis of NHLRC2 in HEK293 cells treated with tBHP and z-VAD-fmk. (b) 738 
Immunoblotting analysis of NHLRC2 in HEK293 cells transduced with retrovirus for 739 
shRNAs for control (sh-Control) or NHLRC2 (sh-NHLRC2-#3 and -#5). (c, d) Analyses 740 
of apoptosis in HEK293cells transduced with retrovirus for sh-Control, sh-NHLRC2-#3 741 
or -#5. (c) Numbers adjacent to the outline indicate the percentage of cells in each area. 742 
(d) The sum of annexin V+PI− and annexin V+PI+ populations in (c) is represented as the 743 
percentage of annexin V+ cells. Data represent the mean ± SD based on three 744 
independent experiments. *P < 0.05. (a–d) Data are representative of three independent 745 
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experiments. 746 








